110 related articles for article (PubMed ID: 6095441)
21. Immunologic cytotoxicity against autologous human lymphocytes transformed or infected by Epstein-Bar virus: role of antibody-dependent cellular cytotoxicity in health individuals.
Aya T; Mizuno F; Osato T
J Natl Cancer Inst; 1980 Aug; 65(2):265-71. PubMed ID: 6249949
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
23. Production of antibody to human osteosarcoma associated antigens by continuous human lymphoblastoid cell lines.
Tsang KY; Pan JF; Fudenberg HH
Immunol Lett; 1984; 7(5):267-72. PubMed ID: 6202625
[TBL] [Abstract][Full Text] [Related]
24. Epstein Barr virus transformation of peripheral blood B cells secreting antibodies reactive with cell surface antigens.
Posner MR; Elboim HS; Tumber MB
Autoimmunity; 1990; 8(2):149-58. PubMed ID: 1966543
[TBL] [Abstract][Full Text] [Related]
25. Serum induced lymphoid cell mediated cytotoxicity to human transitional cell carcinomas of the genitourinary tract.
Hakala TR; Lange PH
Science; 1974 May; 184(4138):795-7. PubMed ID: 4856602
[TBL] [Abstract][Full Text] [Related]
26. Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: identification of its antigen as a neutral glycolipid.
Kingsley EA; Carter TE; Barrow KD; Russell PJ
Cancer Immunol Immunother; 1995 Dec; 41(6):348-54. PubMed ID: 8635192
[TBL] [Abstract][Full Text] [Related]
27. Establishment of specific antibody producing human lines by antigen preselection and Epstein-Barr virus (EBV)-transformation.
Steinitz M; Koskimies S; Klein G; Mäkelä O
J Clin Lab Immunol; 1979 Apr; 2(1):1-7. PubMed ID: 95800
[TBL] [Abstract][Full Text] [Related]
28. [Reactivity of anti-human bladder cancer monoclonal antibodies with bladder tumor tissues].
Kagawa S; Takigawa H; Kurokawa K; Masuko T; Hashimoto Y
Nihon Hinyokika Gakkai Zasshi; 1986 Jan; 77(1):133-9. PubMed ID: 3723905
[No Abstract] [Full Text] [Related]
29. Detection of antigens on transitional cell carcinoma with a xenogeneic antiserum.
Bloom ET
Natl Cancer Inst Monogr; 1978 Dec; (49):57-8. PubMed ID: 86168
[TBL] [Abstract][Full Text] [Related]
30. Production and characterization of monoclonal antibodies to the established human bladder cancer cell lines.
Sasaki M
Keio J Med; 1984 Apr; 33(1):39-56. PubMed ID: 6384610
[No Abstract] [Full Text] [Related]
31. Production of anti-tumor human monoclonal antibodies using different approaches.
Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG
Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684
[TBL] [Abstract][Full Text] [Related]
32. Antibody-dependent autologous lymphocyte cytotoxicity against cells freshly transformed by Epstein-Barr virus.
Aya T; Matsuo T; Takada K; Osato T; Mizuno F
IARC Sci Publ (1971); 1978; (24 Pt 2):711-9. PubMed ID: 221393
[TBL] [Abstract][Full Text] [Related]
33. Autologous antibodies to human bladder cancer.
Grossman HB; Wedemeyer G; Stein J
Cancer Immunol Immunother; 1988; 26(3):269-72. PubMed ID: 3383207
[TBL] [Abstract][Full Text] [Related]
34. Cellular and humoral in vitro cytotoxicity against autologous bladder tumor cells in humans. Differences in autologous cytotoxicity against non-invasive and invasive transitional-cell tumors of the urinary bladder.
Jacobsen F
Acta Pathol Microbiol Scand C; 1981 Aug; 89(4):235-9. PubMed ID: 7315359
[TBL] [Abstract][Full Text] [Related]
35. Detection of onco-fetal bladder antigen in urine of patients with transitional cell carcinoma.
Liu BC; Neuwirth H; Zhu LW; Stock LM; Dekernion JB; Fahey JL
J Urol; 1987 Jun; 137(6):1258-61. PubMed ID: 3295305
[TBL] [Abstract][Full Text] [Related]
36. [Monoclonal antibodies against transitional cell carcinoma assay tumor associated antigens in different grades bladder cancer patients].
Zhang H; Zhao Z; Sun H
Zhonghua Wai Ke Za Zhi; 1996 Sep; 34(9):560-2. PubMed ID: 9594163
[TBL] [Abstract][Full Text] [Related]
37. [The study of mouse monoclonal antibody to human transitional cell carcinoma of the bladder].
Takahashi S; Takahashi N; Takahashi K; Koizumi Y; Kawaguchi T; Togashi S; Suzuki T; Funyu T
Nihon Hinyokika Gakkai Zasshi; 1987 May; 78(5):791-801. PubMed ID: 3694976
[No Abstract] [Full Text] [Related]
38. Monoclonal antibodies to two mouse bladder carcinoma antigens.
Hellström I; Rollins N; Settle S; Chapman P; Chapman WH; Hellström KE
Int J Cancer; 1982 Feb; 29(2):175-80. PubMed ID: 7037659
[TBL] [Abstract][Full Text] [Related]
39. In vitro cytotoxicity studies in bladder and renal cell cancer.
Elhilali MM; Nayak SK
Urology; 1976 May; 7(5):488-91. PubMed ID: 1274005
[TBL] [Abstract][Full Text] [Related]
40. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
